SVRA Latest Press Releases

-- October 21, 2026 --

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment Business Wire 1:10 PM

-- October 12, 2026 --

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 Business Wire 4:05 PM

-- August 24, 2026 --

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 Business Wire 4:05 PM

-- August 20, 2026 --

Savara Announces New Employment Inducement Grant Business Wire 4:05 PM

-- August 11, 2026 --

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:05 PM

-- July 30, 2026 --

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 Business Wire 8:05 AM

-- June 30, 2026 --

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Globe Newswire 7:30 AM

-- June 12, 2026 --

Savara Announces New Employment Inducement Grant Business Wire 4:05 PM

-- June 8, 2026 --

Savara Announces Chief Financial and Administrative Officer Transition Business Wire 4:05 PM

-- May 27, 2026 --

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference Business Wire 4:05 PM

Market Data Delayed 15 Minutes